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SUMMARY
The aim of this study was to develop a LightCycler-based real-time PCR (LC-PCR) assay and to
evaluate its diagnostic use for the detection of Brucella DNA in serum samples. Following
amplification of a 223-bp gene sequence encoding an immunogenetic membrane protein (BCSP31)
specific for the Brucella genus, melting curve and DNA sequencing analysis was performed to verify
the specificity of the PCR products. The intra- and inter-assay variation coefficients were 1.3% and
6.4%, respectively, and the detection limit was 5 fg of Brucella DNA (one genome equivalent). After
optimisation of the PCR assay conditions, a standard curve was obtained with a linear range
(correlation coefficient = 0.99) over seven orders of magnitude from 107 to 10 fg of Brucella DNA.
The LC-PCR assay was found to be 91.9% sensitive and 95.4% specific when tested with 65 negative
control samples and 62 serum samples from 60 consecutive patients with active brucellosis. The
assay is reproducible, easily standardised, minimises the risk of infection in laboratory workers, and
has a total processing time of < 2 h. It could therefore form a promising and practical approach for
the rapid diagnosis of human brucellosis.
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INTRODUCTION
Brucella is one of the world’s major zoonotic
pathogens and is responsible for enormous eco-
nomic losses, as well as considerable human
disease in endemic areas [1]. The heterogeneous
and non-specific clinical symptoms mean that a
diagnosis of brucellosis always requires laborat-
ory confirmation [2]. The diagnostic standard
remains the isolation of Brucella from blood
cultures, as well as from other normally sterile
body fluids and tissues. However, several studies
involving large series of patients with brucellosis
have shown that the sensitivity of blood culture is
only 70–80%, and that this figure may be much
lower in patients with a prolonged clinical course,
with focal forms, or who have received antimi-
crobial therapy previously [3,4]. Furthermore,
results of serological tests are difficult to interpret
in endemic areas or in the context of permanently
exposed individuals.
The high sensitivity and additional advantages
afforded by PCR-based assays for the diagnosis of
human brucellosis now seem proven [5–8]. Nev-
ertheless, the relative complexity of these tech-
niques has hindered their introduction into
clinical laboratories [9]. Unlike classical PCR,
real-time PCR is easy to standardise and does
not require extensive manipulations, so that the
risk of contamination is minimised [10–12]. In
order to simplify the molecular diagnosis of
human brucellosis so that it can be performed
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by any clinical laboratory, a real-time LightCycler
PCR (LC-PCR) assay, based on use of the SYBR
Green I DNA-binding fluorophore dye, was
developed. This article is the first description of
the use of real-time PCR to detect Brucella DNA in
human clinical samples.
MATERIALS AND METHODS
Clinical samples
Patient samples
The study included 62 serum samples taken from 60 consecu-
tive patients diagnosed with active brucellosis in the Infectious
Diseases Units of: Carlos Haya Regional Hospital, Ma´laga;
Virgen del Rocı´o University Hospital, Seville; and Virgen de la
Victoria University Hospital, Malaga, Spain. Two of the
patients provided two samples each, one of which correspon-
ded to an initial episode of disease, while the other corres-
ponded to a relapse after concluding anti-brucella treatment
(after 3 and 4 months, respectively). In 40 (64.5%) episodes,
the diagnosis of brucellosis was established by the isolation of
Brucella from blood culture; in the remaining 22 (35.5%) cases,
diagnosis was based on a compatible clinical picture and the
demonstration of specific antibodies at significant titres or
seroconversion. Significant titres were considered to be a
Wright’s test seroagglutination titre of ‡ 1:160, or an immuno-
capture-agglutination anti-brucella test (see below) titre of
‡ 1:320. All the isolates were identified as Brucella melitensis.
Negative control group
Control blood samples were obtained from 65 individuals;
these comprised 30 patients with febrile syndromes associated
with other defined aetiologies that had initially involved a
differential diagnosis with brucellosis, 15 asymptomatic
patients with a history of brucellosis treated according to
standard antibiotic regimens at least 12 months previously,
ten asymptomatic subjects with persistently high titres of
anti-brucella antibodies who had been exposed in their
occupation to Brucella infection, and ten healthy individuals
(blood donors) with no history of brucellosis or exposure to
Brucella spp.
Bacteriological and serological techniques
Two blood cultures, as well as a range of serological tests,
including the rose Bengal plate agglutination test, Wright’s
seroagglutination test and an immunocapture-agglutination
test (see below), were performed for all patients with active
brucellosis, febrile syndromes of other aetiologies, or a history
of brucellosis. Blood cultures were processed in a semi-
automatic BACTEC 9240 system (Becton Dickinson, Sparks,
MD, USA). Brucella isolation and identification were by
techniques described previously [13]. All isolates were sent
to the National Brucellosis Reference Laboratory in Valladolid,
Spain, for definitive identification and biotyping. The rose
Bengal agglutination test and Wright’s seroagglutination test
were performed as described previously [14], and the immu-
nocapture-agglutination test (Brucellacapt; Vircell SL, Sante Fe´,
Spain) was performed according to the manufacturer’s instruc-
tions [15].
DNA extraction from serum samples
Serum samples for PCR were taken at the same time as the
blood cultures. Two aliquots of serum were conserved at
)20C until processing. DNA was extracted from 200 lL of
serum, placed in a 0.5-mL microcentrifuge tube, and centri-
fuged for 15 min at 15 000 g. The supernatant was discarded
and the pellet was resuspended in 200 lL of sterile water and
centrifuged for 10 min at 15 000 g. The supernatant was again
discarded and the pellet was resuspended in 40 lL of sterile
water, placed in a boiling water bath for 10 min, cooled on ice,
and then centrifuged for 10 s at 15 000 g before being stored at
)20C until use. Aliquots (2 lL) of the suspension (template
DNA) were used for PCR analysis.
Real-time PCR with SYBR Green I
Primers were designed from the conserved region of the gene
encoding an immunogenic membrane protein of 31 kDa
(BCSP31) of Brucella abortus that is specific to the Brucella
genus and present in all known biovars [16]. The 21-mer
primers used in the amplification process were forward primer
B4 (5¢-TGGCTCGGTTGCCAATATCAA-3¢) and reverse primer
B5 (5¢-CGCGCTTGCCTTTCAGGTCTG-3¢) (Tib Molbiol, Berlin,
Germany) [17]. PCRs were performed in 20-lL final volumes
in capillary tubes in a LightCycler instrument (Roche Diag-
nostic, Mannheim, Germany). Reaction mixtures contained
2 lL of LightCycler FastStart DNA mastermix for SYBR Green
I (Roche Diagnostic), 0.5 lM each primer, 4 mM MgCl2 and
2 lL of template DNA. All capillaries were sealed, centrifuged
at 500 g for 5 s, and then amplified in a LightCycler instru-
ment, with activation of polymerase (95C for 10 min), fol-
lowed by 45 cycles of 10 s at 95C, 10 s at 60C, and 9 s at 72C.
The temperature transition rate was 20C ⁄ s for all steps.
Double-stranded PCR product was measured during the 72C
extension step by detection of fluorescence associated with the
binding of SYBR Green I to the product. Fluorescence curves
were analysed with LightCycler software v. 3.5.
Melting curve analysis was performed immediately after
the amplification protocol under the following conditions: 0 s
(hold time) at 95C, 15 s at 71C and 0 s (hold time) at 95C.
Temperature change rates were 20C ⁄ s, except in the final step,
which was 0.1C ⁄ s. The melt peak generated represented the
specific amplified product. The crossing point (Cp) was
defined as the maximum of the second derivative from the
fluorescence curve.
Positive controls were included in all tests and comprised
serial dilutions of B. abortus B-19 DNA from 103 fg to 5 fg;
negative controls were also included and contained all the
elements of the reaction mixture except template DNA. All
samples were processed in duplicate. Universal precautions
and one-way flow of DNA extraction and amplification were
used to prevent contamination. To avoid potential observer
bias, the status of each patient concerning Brucella infection
was unknown during the PCR assay.
Sequencing of LC-PCR product
In order to confirm the identities of the amplified fragments,
the LC-PCR products were sequenced at the Laboratorio de
Secuenciacio´n de Sistemas Geno´micos (Valencia, Spain). The
ABI PRISM BigDye Terminator Cycle sequencing reaction kit
v. 3.0 (Applied Biosystems, Madrid, Spain) was used for the
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sequencing reactions. Sequence analysis was performed by
capillary electrophoresis in an ABI PRISM model 3100 auto-
mated sequencer (Applied Biosystems).
Statistical analysis
Data were analysed using SPSS v. 10.0 for Windows (SPSS Inc.,
Chicago, IL, USA). Student’s t-test was used for comparison of
means, and chi-square and Fisher’s tests were used for
comparison of proportions. Non-parametric Spearman corre-
lation coefficients were used to assess the association between
continuous variables. All tests were two-tailed, and p values
< 0.05 were accepted as statistically significant. To evaluate the
assay precision, intra- and inter-assay coefficients of variation
(CV) were calculated. The sensitivity, specificity, positive and
negative predictive values, and likelihood ratios were calcu-
lated by two-by-two analysis.
RESULTS
Analytical sensitivity
The LC-PCR assay successfully amplified 10 fg of
Brucella DNA in a ten-fold serial dilution of a pure
culture of B. abortus B-19 (Fig. 1A). The detection
limit of the method in 200 lL of serum sample
spiked with serial dilutions of B. abortus B-19 was
one bacterial cell (equivalent to 5 fg of DNA).
Fig. 1B shows the correlation between log DNA
concentrations and the Cp values. Amplicon-
specific signals with melting temperatures of
88.16 ± 0.05C are shown in Fig. 2. The melting
curve revealed no presence of primer-dimers.
Reproducibility
The intra-assay variability was determined by
amplifying, in quadruplicate, dilutions of a pure
culture of B. abortus B-19, equivalent to 100, 50, 10
and 5 fg of Brucella DNA. Cp values obtained for
the same dilutions on seven different days were
used to determine the inter-assay variability. The
mean CV for intra-assay repetitions was 1.3%,
with CV values of 0.9%, 1.9%, 0.9% and 1.4% for
the samples with 100, 50, 10 and 5 fg of Brucella
DNA, respectively. The inter-assay CV was 6.45%
for the entire group of samples, and was 2.6%,
6.3%, 8.7% and 8.1% for the samples with 100, 50,
10 and 5 fg of Brucella DNA, respectively.
Detection of Brucella spp. in serum samples
Of the 62 samples from patients with brucellosis,
57 (91.9%) were positive in the LC-PCR assay and
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Fig. 1. Examples of LightCycler
(LC) printouts showing detection of
Brucella DNA by the LC-PCR assay.
(A) Fluorescent signal related to cycle
number on a panel of ten-fold
dilutions between 107 and 10 fg of
Brucella abortus B-19 DNA. Brucella
DNA samples were amplified in
duplicate for 45 cycles. (B) Logarith-
mic standard curve of (A). Cp values
are plotted against decreasing con-
centrations of Brucella DNA. The
slope is ) 2.89 cycles ⁄ log10 and the
correlation coefficient is 0.99.
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five (8.1%) were negative. Four of the five
patients with false-negative results had positive
blood cultures. In three of the five (4.8% of the
total sample), the LC-PCR was positive following
a second extraction and amplification of the same
serum sample. The melting temperature for all
Brucella-positive samples was consistent with that
produced by the standard curve. The identity of
the PCR product was confirmed by determining
the nucleotide sequence of the amplified frag-
ment, which matched exactly the B. abortus
(BCSP31) DNA sequence described previously
[5].
In the negative control group, 62 (95.4%) sam-
ples failed to produce exponential fluorescence
curves during the LC-PCR, but three (4.6%)
yielded a positive LC-PCR assay result. Two of
these three samples, considered to be false-posi-
tive, were from patients (a farmer and a shepherd)
who had habitual contact with sheep and goats
during their work, while the third was from a
female who sometimes ate unpasteurised cheese.
Overall, the sensitivity and specificity of the
serum LC-PCR assay were 91.9% and 96.4%,
respectively. The positive and negative predictive
values, and positive and negative likelihood
ratios, were 95.0%, 92.5%, 19.9% and 0.08%,
respectively. The mean Cp values ranged from
29.9 ± 3.3 cycles for patients with active brucello-
sis to 35.0 ± 4.2 cycles for the three negative
control patients who yielded a positive LC-PCR
assay result (p 0.013).
DISCUSSION
The advent of the LightCycler and real-time PCR
has provided an opportunity to develop an assay
that meets the requirements for rapid diagnosis.
This technology offers a significant improvement
for the detection of infections with Brucella spp. In
addition, the use of sealed capillary tubes in the
LightCycler format, combined with the absence of
post-amplification manipulation of PCR products,
reduces significantly the risk of contamination
resulting from amplicon carryover.
PCR analysis of several blood fractions, inclu-
ding whole blood, mononuclear leukocytes and
serum, has been used to identify Brucella DNA
in patients with brucellosis [5,8,18]. Because
members of the Brucella genus are facultative
intracellular pathogens, and the inoculum found
in patients with brucellosis is normally very low
[19], most studies of the diagnostic yield of PCR
assays in human brucellosis have been under-
taken with whole blood samples. Although this
type of sample has the advantage of providing
the maximum possible number of target bac-
teria, the presence of potential PCR inhibitors
makes the assay more technically difficult to
perform [20].
Multiple reasons justify the use of a simple
SYBR Green I dye format to provide the fluores-
cent signal. First, the 223-bp target amplified is
very specific to the Brucella genus and is present
in all its biovars. Second, melting curve analysis
of the amplified DNA allows clear distinction of
the specific products from artefacts, such as
primer-dimers, which are also minimised by the
FastStart step included in the procedure. Third,
treatment of Brucella infection is the same, irres-
pective of the causative species of Brucella. Fourth,
this approach is simpler and less costly, since
many fluorescent labels, rather than a single
molecule, are incorporated into the amplified
fragment [21,22].
The analytical sensitivity of the LC-PCR assay
was higher than those of conventional PCR
procedures, followed by dot-blot hybridisation
and PCR-ELISA, as 5 fg of bacterial DNA was
amplified successfully. Such amounts of DNA can
be expected in any blood sample from a patient
with active brucellosis. The precision of the assay,
with an intra-assay variation of < 1.5% and an
inter-assay variation of < 6.5%, was similar to or
lower than that of other PCR assays based on
similar principles [23], while the diagnostic yield
was 91.9%, i.e., far higher than that for blood
cultures [3,4]. Melting curve analysis increased
the specificity of the assay by confirming that a
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Fig. 2. Examples of LightCycler (LC) printouts showing
melting curves of the amplified fragments generated by the
LC-PCR assay. Specific signals had melting temperatures
of 88.16 ± 0.05C.
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positive fluorescence signal obtained during the
real-time PCR was associated with an amplified
product with a characteristic Tm. Melting curve
analysis showed that all Brucella-positive speci-
mens and positive controls returned the same Tm,
indicating that the LightCycler primer sequences
were highly conserved.
The existence of five (8.1%) false-negative
results, some in patients with positive blood
cultures, was surprising. Although some of these
false-negatives could result from the presence of
inhibitors in the sample, this is unlikely. Zerva
et al. [18], using a similar volume of serum, found
6% false-negative results by conventional PCR
methods. The small reaction volume used in the
LC-PCR systems poses a potential disadvantage
compared to conventional PCR, since only a small
volume of template can be added to the master-
mix. The use of very small volume samples from
patients with low concentrations of circulating
brucellae could result in an absence of target
DNA in the sample tested. Three of the patients
who yielded an initial negative result were pos-
itive following a second extraction from the same
serum sample. These findings suggest that
increasing the sample volume, or performing a
second test for borderline results, may increase
the sensitivity of the assay. In either case, if the
assay is to be used regularly for routine diagnostic
purposes, it would be advisable to include an
internal amplification control in the assay to
monitor PCR inhibition.
The assay was considered to have good spe-
cificity. Of the three negative control samples with
apparent false-positive results, two were from
patients who were exposed continuosly to Brucella
spp. during their employment, and the other was
from a patient who consumed unpasteurised
cheese. Since the B4 and B5 primers used have
been shown to be highly specific for Brucella spp.
[24], Brucella-specific DNA might have been pre-
sent in these samples. Therefore, these patients
could either be false-positive or have oligosymp-
tomatic or asymptomatic self-limiting forms of
infection [25,26]. Nevertheless, these findings
suggest that caution is needed in the interpret-
ation of a positive result from an individual who
is exposed regularly to Brucella. The high sensi-
tivity of PCR-based methods enables the amplifi-
cation of possible remnants of circulating DNA in
asymptomatic subjects, although these have no
clinical relevance [10].
Although the present results show that the
mean Cp values of the patients with brucellosis
were significantly lower than those of the
patients considered to be false-positive, the
quantification method used in this study is not
very precise, as there is a large overlap between
the Cp values of both groups. The preparation
and use of recombinant plasmids may enable a
DNA threshold to be defined which correlates
with active infection.
Overall, the results of this study agree with
those reported previously [5–7,18,27]. Neverthe-
less, before the molecular diagnosis of brucellosis
can become a clinical reality, studies aimed at
harmonising the extraction and amplification
protocols are required, as well as verification of
inter-laboratory reproducibility. However, the
LC-PCR assay described in this study could be a
practical and useful tool for the rapid diagnosis of
human brucellosis. It is highly sensitive and
specific, is easy to perform and could provide
results to a clinician in < 2 h. In addition, the risks
to laboratory personnel associated with handling
the microorganism are minimised [28].
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